Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of Gamma knife radiosurgery followed by bevacizumab plus erlotinib in patients with IDH mutant glioma
KCT0010995Phase 2Not yet recruiting
- Sponsor
- Boryung
- Start
- Oct 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, erlotinib in glioma, sponsored by Boryung. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
bevacizumaberlotinib
03
Conditions
glioma
Beyond the preview
Go deeper on KCT0010995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010995.